Literature DB >> 20164239

Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.

Artemis P Vogazianou1, Raymond Chan, L Magnus Bäcklund, Danita M Pearson, Lu Liu, Cordelia F Langford, Simon G Gregory, V Peter Collins, Koichi Ichimura.   

Abstract

We studied the status of chromosomes 1 and 19 in 363 astrocytic and oligodendroglial tumors. Whereas the predominant pattern of copy number abnormality was a concurrent loss of the entire 1p and 19q regions (total 1p/19q loss) among oligodendroglial tumors and partial deletions of 1p and/or 19q in astrocytic tumors, a subset of apparently astrocytic tumors also had total 1p/19q loss. The presence of total 1p/19q loss was associated with longer survival of patients with all types of adult gliomas independent of age and diagnosis (P = .041). The most commonly deleted region on 19q in astrocytic tumors spans 885 kb in 19q13.33-q13.41, which is telomeric to the previously proposed region. Novel regions of homozygous deletion, including a part of DPYD (1p21.3) or the KLK cluster (19q13.33), were observed in anaplastic oligodendrogliomas. Amplifications encompassing AKT2 (19q13.2) or CCNE1 (19q12) were identified in some glioblastomas. Deletion mapping of the centromeric regions of 1p and 19q in the tumors that had total 1p/19q loss, indicating that the breakpoints lie centromeric to NOTCH2 within the pericentromeric regions of 1p and 19q. Thus, we show that the copy number abnormalities of 1p and 19q in human gliomas are complex and have distinct patterns that are prognostically predictive independent of age and pathological diagnosis. An accurate identification of total 1p/19q loss and discriminating this from other 1p/19q changes is, however, critical when the 1p/19q copy number status is used to stratify patients in clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20164239      PMCID: PMC2940668          DOI: 10.1093/neuonc/nop075

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  51 in total

Review 1.  Notch signalling in vertebrate neural development.

Authors:  Angeliki Louvi; Spyros Artavanis-Tsakonas
Journal:  Nat Rev Neurosci       Date:  2006-02       Impact factor: 34.870

2.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.

Authors:  Yuri Kotliarov; Mary Ellen Steed; Neil Christopher; Jennifer Walling; Qin Su; Angela Center; John Heiss; Mark Rosenblum; Tom Mikkelsen; Jean C Zenklusen; Howard A Fine
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

3.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Authors:  Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

4.  Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

Authors:  Constance A Griffin; Peter Burger; Laura Morsberger; Raluca Yonescu; Sharon Swierczynski; Jon D Weingart; Kathleen M Murphy
Journal:  J Neuropathol Exp Neurol       Date:  2006-10       Impact factor: 3.685

5.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.

Authors:  K Ichimura; M B Bolin; H M Goike; E E Schmidt; A Moshref; V P Collins
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

6.  Notch1 and notch2 have opposite effects on embryonal brain tumor growth.

Authors:  Xing Fan; Irina Mikolaenko; Ihab Elhassan; Xingzhi Ni; Yunyue Wang; Douglas Ball; Daniel J Brat; Arie Perry; Charles G Eberhart
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

7.  Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19.

Authors:  Christian Hartmann; Loki Johnk; Gaspar Kitange; Yanhong Wu; Linda K Ashworth; Robert B Jenkins; David N Louis
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 8.  The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors.

Authors:  Elena Kolomietz; M Stephen Meyn; Ajay Pandita; Jeremy A Squire
Journal:  Genes Chromosomes Cancer       Date:  2002-10       Impact factor: 5.006

9.  Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

Authors:  Michael Weller; Hilmar Berger; Christian Hartmann; Johannes Schramm; Manfred Westphal; Matthias Simon; Roland Goldbrunner; Dietmar Krex; Joachim P Steinbach; Christoph B Ostertag; Markus Loeffler; Torsten Pietsch; Andreas von Deimling
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  24 in total

1.  Exploring drivers of gene expression in the Cancer Genome Atlas.

Authors:  Andrea Rau; Michael Flister; Hallgeir Rui; Paul L Auer
Journal:  Bioinformatics       Date:  2019-01-01       Impact factor: 6.937

2.  Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis.

Authors:  Shuko Harada; Lindsay B Henderson; James R Eshleman; Christopher D Gocke; Peter Burger; Constance A Griffin; Denise A S Batista
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

3.  A case for reclassifying infiltrating gliomas in adults.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  J Neurooncol       Date:  2012-07-20       Impact factor: 4.130

Review 4.  Advances in the molecular genetics of gliomas - implications for classification and therapy.

Authors:  Guido Reifenberger; Hans-Georg Wirsching; Christiane B Knobbe-Thomsen; Michael Weller
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

Review 5.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 6.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

7.  A new method of identifying glioblastoma subtypes and creation of corresponding animal models.

Authors:  Xia Zhou; Gonghua Li; Sanqi An; Wen-Xing Li; Huihui Yang; Yicheng Guo; Zhi Dai; Shaoxing Dai; Junjuan Zheng; Jingfei Huang; Antonio Iavarone; Xudong Zhao
Journal:  Oncogene       Date:  2018-05-17       Impact factor: 9.867

8.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

Authors:  Kristen L Drucker; Alex R Paulsen; Caterina Giannini; Paul A Decker; Sachiko I Blaber; Michael Blaber; Joon H Uhm; Brian P O'Neill; Robert B Jenkins; Isobel A Scarisbrick
Journal:  Neuro Oncol       Date:  2013-01-10       Impact factor: 12.300

9.  MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Authors:  Marta Mellai; Oriana Monzeglio; Angela Piazzi; Valentina Caldera; Laura Annovazzi; Paola Cassoni; Guido Valente; Susanna Cordera; Cristina Mocellini; Davide Schiffer
Journal:  J Neurooncol       Date:  2012-05       Impact factor: 4.506

Review 10.  The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Daniel P Cahill; Andrew E Sloan; Brian V Nahed; Kenneth D Aldape; David N Louis; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.